Navigation Links
European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.'s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application
Date:7/6/2009

SEATTLE, July 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it had requested and the EMEA has agreed to an oral explanation in support of the OPAXIO Marketing Authorization Application (MAA) in September, 2009 extending the review for the Committee for Medicinal Products for Human Use (CHMP) opinion on approval until Q4-2009. In April, 2008 the EMEA accepted for review the MAA for OPAXIO for first-line treatment of patients with advanced non-small cell lung cancer who are performance status 2, based on a non-inferior survival and improved side effect profile. The previously scheduled June, 2009 meeting with the EMEA on OPAXIO did not occur due to conflicts in regulatory schedule as CTI focused on completing the pixantrone New Drug Application (NDA) submission in June, 2009.

"We are pleased that the EMEA has agreed to an in person oral explanation in September allowing the Company and its lung cancer experts adequate time to prepare a thorough review for the Co-rapporteurs in support of our MAA for OPAXIO in non-small cell lung cancer," said James A. Bianco, M.D., CEO of Cell Therapeutics. "The fourth quarter is shaping up to be a pivotal period for the Company."

About OPAXIO(TM)

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors du
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
3. Medical Services International Inc. Completes Testing for European Union (EU) Application
4. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
5. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
6. Launch of second European Cancer Research Funding survey
7. European directive will halt use of MRI scans; cancer diagnosis and treatment will suffer
8. Pharsight to Host European Software Conference
9. OmniGuide Begins European Commercialization
10. Paving the way for future pan-European clinical trials
11. US, European cancer educators gather in Alabama for meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... ,, NEW YORK, Dec. 2 ...lliative care coordination, Advanced Illness Coor...pitalizations in the last years of life as well as... family caregivers without increasing mortality. T...lished in American Journal of Managed Care (Nove...
(Date:12/2/2009)...DENA, Calif.Researchers from the California Instit... in detail, and for the first time, the previously...ein called ubiquitin are added by enzymes called u... cycle. Ubiquitin chains tag target proteins for d...ell. , "We found that ubiquitin ligases build ub...
(Date:12/2/2009)...DRIA, VA Constraint-induced movement therapy (CIM... for children with hemiplegic cerebral palsy, but ...atic review published in the November issue of Ph...he American Physical Therapy Association (APTA). T...and 2 systematic reviews, concluded that further r...
(Date:12/2/2009)... National Race Series to increase...their families on the importance of early detectio...cember 2, 2009 -- Men, women, families, friends an...are invited to participate in the Rudolph Ramble 5...l PACE Race Series , which was launched by the P...
(Date:12/2/2009)..., ATLANTA, Dec. 2 In response t... military, FamilyLife, a non-profit ministry dedic...esent its Weekend to Remember® marriage con...les in Atlanta from Dec. 11 - 13 at the Grand Hyat...Weekend to Remember is a marriage getaway aimed a...
Breaking Medicine News(10 mins):Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 2Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 3Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 4Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 2Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 3Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 4Health News:Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy 2Health News:PACE Race Returns with Denver's Rudolph Ramble 2Health News:PACE Race Returns with Denver's Rudolph Ramble 3Health News:PACE Race Returns with Denver's Rudolph Ramble 4Health News:FamilyLife Supports Military Marriages in Atlanta 2
...xer shorts in football prints and innerwear with n...ear// and lingerie designers are experimenting wit...nding toward discreet colors and forms with a hint...so opulent, rather more discreet," said Alexandra ...
...e Canadian Tumour Repository Network is making ava...chers all over the world in order to help them get... hailing this step as a major one that will go a l...e it is multiple diseases, you have to have multip...
...e first human bird flu related death has been repo...ntry. Laboratory examinations revealed that the 30...f the highly pathogenic H5N1 strain of bird flu. ... flu-like symptoms, the health ministry said in a ...
... India the only laboratory equipped to handle the ...om across the country. Tiny vials of chicken blood...e boxes. // These samples are sent by the farmers ...e High Security Animal Disease Laboratory in Bhopa...
...athioprine, an immunosuppressant, meant for use in...ment of eczema, a skin disorder. The drug was disc...rejection of transplanted kidneys// in renal failu...g, a combination of azathioprine and corticosteroi...
... the direction of development of prosthetic limbs ...artificial, super-strength muscles which are power...n Science, these artificial muscles are 100 times ...xas in Dallas, working with colleagues from South ...
Other Medicine News:Health News:Romantic and discreet trends in lingerie 2Health News:Azathioprine Can Soon Revolutionize Eczema Treatment 2
(Date:12/1/2009)... , MONTREAL and DUSSELDORF, Germany, Dec. 1 /...anufacturer of specialized graphics solutions, is ...ow shipping the Matrox Xenia(TM) Series display c...ammography solutions using Fujifilm Synapse. ,...uter based radiography, offering the world,s first...
(Date:12/1/2009)..., NEW YORK, Dec. 1 Reportlinker...s available in its catalogue: ,, Medical Oxyg...http://www.reportlinker.com/p0164334/Medical-Oxyge..., Worldwide medical oxygen systems market for home...coming years. The buoyant growth expectations stem...
(Date:12/1/2009)...WHITEHOUSE STATION, N.J., Dec. 1 M... Food and Drug Administration (FDA) has approved Z...e 1100 mg capsules), for over-the-counter treatmen...eted over-the-counter by Schering-Plough HealthCar... of Merck & Co., Inc. Schering-Plough and Merc...
Breaking Medicine Technology:FUJIFILM Europe Teams Synapse with Matrox Xenia 2FUJIFILM Europe Teams Synapse with Matrox Xenia 3Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 2Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 3Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 4Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 5Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 6Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 7FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 2FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 3FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 4Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 1Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 2Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 3Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 4Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 5Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 6Caraco Pharmaceutical Laboratories Ltd Markets Generic Imitrex 28R 29 Tablets 54270 1Caraco Pharmaceutical Laboratories Ltd Markets Generic Imitrex 28R 29 Tablets 54270 2Noted Vertebroplasty Expert Cites Concerns About Recently Published Study 54266 1Noted Vertebroplasty Expert Cites Concerns About Recently Published Study 54266 2
...est Pipettor , , The Shortyavailable with both Im...ow our face-to-face relationship with the scientif...ucts that make pipetting easier and more effective...nnel pipettors., Gets you closer to the working ...
BioPette E Electronic Pipettor, 10-200l
Finnpipette BioControl Single Channel, 40-200ul
...ctronic Pipette is ideal for all liquid handling a...display, ergonomically-placed operating buttons, a..., dispensing, reverse pipetting and diluting make ...mple functions of a manual pipette without any adv...
Medicine Products: